Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in combination with anti-tumor medications in KRAS G12D mutant advanced solid tumors
NCT06385678Phase 2Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in solid tumor, sponsored by Hengrui. Started Jul 2024; status: active, not recruiting.
02
Drugs
HRS-4642
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06385678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385678.